Author: admin

DelveInsight’s, “High-Grade Glioma Pipeline Insight 2024” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in High-Grade Glioma pipeline landscape. It covers the High-Grade Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the High-Grade Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in High-Grade Glioma Research. Learn more about our innovative pipeline today! @ High-Grade Glioma Pipeline Outlook

Key Takeaways from the High-Grade Glioma Pipeline Report

• June 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy. The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
• June 2024:- PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways. Nationwide Children’s Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
• June 2024:- Plus Therapeutics- This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.
• DelveInsight’s High-Grade Glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for High-Grade Glioma treatment.
• The leading High-Grade Glioma Companies such as Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee’s Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
• Promising High-Grade Glioma Therapies such as BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.

Stay informed about the cutting-edge advancements in High-Grade Glioma Treatments. Download for updates and be a part of the revolution in cancer care @ High-Grade Glioma Clinical Trials Assessment

High-Grade Glioma Emerging Drugs Profile

• OT101: Mateon Therapeutics

OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult High-Grade Glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.

• BMX-001: BioMimetix

BMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed High-Grade Glioma patients who are being treated with brain radiation and temozolomide. 

• OKN-007: Oblato, Inc.

OKN-007 is being developed by Oblato, Inc for the treatment of High-Grade Glioma. It is currently in phase I/II stage of development.

• PTC596: PTC Therapeutics

PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.

Learn more about High-Grade Glioma Drugs opportunities in our groundbreaking High-Grade Glioma Research and development projects @ High-Grade Glioma Unmet Needs

High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Molecule Type

High-Grade Glioma Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Discover the latest advancements in High-Grade Glioma Treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ High-Grade Glioma Market Drivers and Barriers, and Future Perspectives

Scope of the High-Grade Glioma Pipeline Report

• Coverage- Global
• High-Grade Glioma Companies- Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee’s Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
• High-Grade Glioma Therapies- BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.
• High-Grade Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• High-Grade Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of High-Grade Glioma Pipeline on our website @ High-Grade Glioma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. High-Grade Glioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. High-Grade Glioma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. High-Grade Glioma Collaboration Deals
9. Late Stage Products (Phase III)
10. OT101: Mateon Therapeutics
11. Mid Stage Products (Phase II and Phase I/II)
12. BMX-001: BioMimetix
13. OKN-007: Oblato, Inc.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. PTC596: PTC Therapeutics
17. Drug profiles in the detailed report…..
18. Pre-clinical and Discovery Stage Products
19. Drug Name: Company Name
20. Inactive Products
21. High-Grade Glioma Key Companies
22. High-Grade Glioma Key Products
23. High-Grade Glioma- Unmet Needs
24. High-Grade Glioma- Market Drivers and Barriers
25. High-Grade Glioma- Future Perspectives and Conclusion
26. High-Grade Glioma Analyst Views
27. High-Grade Glioma Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: High-Grade Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diffuse Intrinsic Pontine Glioma Research. Learn more about our innovative pipeline today! @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report

• June 2024:- Nationwide Children’s Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
• June 2024:- Pfizer- A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1).
• DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
• The leading Diffuse Intrinsic Pontine Glioma Companies such as Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
• Promising Diffuse Intrinsic Pontine Glioma Therapies such as Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.

Stay informed about the cutting-edge advancements in Diffuse Intrinsic Pontine Glioma Treatments. Download for updates and be a part of the revolution in disease care @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile

• MTX 110: Midatech

MTX110 is a water‐soluble form of panobinostat free base, achieved through complexation with hydroxypropyl‐β‐ cyclodextrin (HPBCD) that enables convection‐enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non‐selective histone deacetylase inhibitor (pan‐HDAC inhibitor). Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma. MTX110 is delivered directly into and around the patient’s tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood‐brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient‐derived DIPG cell lines.

• Paxalisib: Kazia Therapeutics

Paxalisib (originally GDC-0084) was invented by Genentech, Inc (South San Francisco, CA), the most successful developer of new cancer medicines in the world. Kazia entered into a worldwide exclusive license agreement with Genentech in October 2016. Genentech designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The distinguishing feature of paxalisib is its ability to cross the blood-brain barrier (BBB). Ordinarily, the BBB prevents many drugs from reaching brain tissue, and is a challenge in the treatment of any disease in the central nervous system. Paxalisib has been designed to cross the BBB, and a wealth of experimental data shows that it does so very successfully. This feature of paxalisib is almost unique in this class of medicines and differentiates it from the approved products in the PI3K inhibitor class.

Learn more about Diffuse Intrinsic Pontine Glioma Drugs opportunities in our groundbreaking H Diffuse Intrinsic Pontine Glioma Research and development projects @ Diffuse Intrinsic Pontine Glioma Unmet Needs

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Diffuse Intrinsic Pontine Glioma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspectives

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report

• Coverage- Global
• Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
• Diffuse Intrinsic Pontine Glioma Therapies- Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Diffuse Intrinsic Pontine Glioma Pipeline on our website @ Diffuse Intrinsic Pontine Glioma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Diffuse Intrinsic Pontine Glioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diffuse Intrinsic Pontine Glioma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. MTX 110: Midatech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diffuse Intrinsic Pontine Glioma Key Companies
21. Diffuse Intrinsic Pontine Glioma Key Products
22. Diffuse Intrinsic Pontine Glioma- Unmet Needs
23. Diffuse Intrinsic Pontine Glioma- Market Drivers and Barriers
24. Diffuse Intrinsic Pontine Glioma- Future Perspectives and Conclusion
25. Diffuse Intrinsic Pontine Glioma Analyst Views
26. Diffuse Intrinsic Pontine Glioma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Intrinsic Pontine Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent Glioblastoma Research. Learn more about our innovative pipeline today! @ Recurrent Glioblastoma Pipeline Outlook

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

• June 2024:- CarThera– A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
• June 2024:- Darell Bigner– The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
• June 2024:- Eli Lilly and Company– A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer.
• DelveInsight’s Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
• The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, and others.
• Promising Recurrent Glioblastoma Therapies such as Pembrolizumab, Olaparib, Temozolomide, VB11, GX-I7, ASC40, VXM01, Carboplatin, Lomustine, Ipilimumab, MN-166, Lerapolturev, and others.

Stay informed about the cutting-edge advancements in Recurrent Glioblastoma Treatments. Download for updates and be a part of the revolution in neurology care @ Recurrent Glioblastoma Clinical Trials Assessment

Recurrent Glioblastoma Emerging Drugs Profile

• ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

• GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

• Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

• VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

Learn more about Recurrent Glioblastoma Drugs opportunities in our groundbreaking Recurrent Glioblastoma Research and development projects @ Recurrent Glioblastoma Unmet Needs

Recurrent Glioblastoma Market Drivers

• Incidence of Glioblastoma multiforme is high
• Increasing R&D on novel therapies and combination therapies

Recurrent Glioblastoma Market Barriers

• Lack of uniform definition and criteria for tumor recurrence
• Heterogeneous nature of the disease

Discover the latest advancements in Recurrent Glioblastoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Neurology @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent Glioblastoma Pipeline Report

• Coverage- Global
• Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, and others.
• Recurrent Glioblastoma Therapies- Pembrolizumab, Olaparib, Temozolomide, VB11, GX-I7, ASC40, VXM01, Carboplatin, Lomustine, Ipilimumab, MN-166, Lerapolturev, and others.
• Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Recurrent Glioblastoma Pipeline on our website @ Recurrent Glioblastoma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Recurrent Glioblastoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ASC40: Ascletis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GX-I7: Genexine
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. VXM01: VAXIMM AG
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Recurrent Glioblastoma Key Companies
21. Recurrent Glioblastoma Key Products
22. Recurrent Glioblastoma- Unmet Needs
23. Recurrent Glioblastoma- Market Drivers and Barriers
24. Recurrent Glioblastoma- Future Perspectives and Conclusion
25. Recurrent Glioblastoma Analyst Views
26. Recurrent Glioblastoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Glioblastoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook

Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report

• June 2024:- Bayer- A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) – CHRONOS-3. The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
• June 2024:- ImmPACT Bio– This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy.
• June 2024:- Regeneron Pharmaceuticals– The study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how effective the study drug is compared to standard of care (SOC) therapy.
• DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
• The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
• Promising B-Cell Non-Hodgkin Lymphoma Therapies such as CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.

Stay informed about the cutting-edge advancements in B-Cell Non-Hodgkin Lymphoma Treatments. Download for updates and be a part of the revolution in care @ B-Cell Non-Hodgkin Lymphoma Clinical Trials Assessment

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile

Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

• MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

• CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

• LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

Learn more about B-Cell Non-Hodgkin Lymphoma Drugs opportunities in our groundbreaking B-Cell Non-Hodgkin Lymphoma Research and development projects @ B-Cell Non-Hodgkin Lymphoma Unmet Needs

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in B-Cell Non-Hodgkin Lymphoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatic Tumor Market Drivers and Barriers, and Future Perspectives

Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report

• Coverage- Global
• B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others.
• B-Cell Non-Hodgkin Lymphoma Therapies- CD19 CAR-T cells, HY004, Glofitamab, Atezolizumab, Obinutuzumab, Copanlisib (Aliqopa, BAY80-6946), Rituximab, Odronextamab, DZD8586, IMPT-314, and others.
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of B-Cell Non-Hodgkin Lymphoma Pipeline on our website @ B-Cell Non-Hodgkin Lymphoma Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. B-Cell Non-Hodgkin Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Valemetostat: Daiichi Sankyo
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB-010: Caribou Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. B-Cell Non-Hodgkin Lymphoma Key Companies
21. B-Cell Non-Hodgkin Lymphoma Key Products
22. B-Cell Non-Hodgkin Lymphoma- Unmet Needs
23. B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
24. B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
25. B-Cell Non-Hodgkin Lymphoma Analyst Views
26. B-Cell Non-Hodgkin Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Non-Hodgkin Lymphoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight